Chinese biopharmaceutical products company Sinovac Biotech has received $15m in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac.
Advantech Capital and Vivo Capital have invested $7.5m each in Sinovac subsidiary Sinovac Research and Development. The investment is said to convert into 7.5% of the total equity interest in Sinovac R&D.
Sinovac started developing the inactivated vaccine against Covid-19 in January this year in collaboration with academic research institutes in China.
In preclinical studies, the vaccine candidate was found to be safe and provided protection to rhesus macaques monkeys. Findings were published in Science journal.